Cardiovalve

Developer of a novel transcatheter valve replacement system for mitral and tricuspid valve replacement.

Health Tech & Life Sciences
Acquired by Venus Medtech
Acquired Or Yehuda, Israel Founded 2010
Last updated 2026-07-20
Total raised
$45.5M
Last: Undisclosed Round 2020-08
Stage
Acquired
Founded
2010
Headcount
125
HQ
Or Yehuda, Israel
Sector
Health Tech & Life Sciences

About

Cardiovalve developed a transcatheter valve replacement system designed to treat both mitral and tricuspid anatomies. The system is delivered transfemorally, avoiding the need for open-heart surgery, and offers benefits such as a short profile to minimize ventricular protrusion, a robust anchoring mechanism, and an enhanced sealing solution to prevent paravalvular leaks. Cardiovalve was originally a spin-off of Valtech Cardio, which was acquired by Edwards Lifesciences in 2017.

Funding history · 2 rounds · $45.5M total

2020-07
Undisclosed Round $40.0M
★ Amir Gross★ NGN Capital★ OXO Ventures★ GlenRock Group★ Peregrine Ventures★ Edwards Lifesciences
2016-10
Undisclosed Round $5.5M
★ Peregrine Ventures

Headcount over time

From 49 (2022-10) to 40 (2026-07) · -9 (-18%) · 16 points · source: Finder history + radar grounding
610 2022-10 2026-07

Q&A

What is Cardiovalve's primary focus?
Cardiovalve develops cardiovascular replacement devices for minimally invasive surgery, specifically focusing on a transfemoral system to replace the mitral valve.
When was Cardiovalve acquired and by whom?
Cardiovalve was acquired by Venus Medtech in March 2022.
What is the status of Cardiovalve's FDA approvals?
Cardiovalve received FDA approval for an Early Feasibility Study of its Transcatheter Tricuspid Valve Replacement System and has been granted Breakthrough Device Designation status by the FDA.
What was Cardiovalve's total funding raised before its acquisition?
Cardiovalve raised a total of $45,483,000.
Who were the investors in Cardiovalve's August 2020 funding round?
In August 2020, Cardiovalve received funding from investors including Edwards Lifesciences.
What is Cardiovalve's employee count?
Cardiovalve has 51–200 employees.
Who is the CEO of Cardiovalve?
Amir Gross is the CEO of Cardiovalve and also a founder.
What is Cardiovalve's connection to Valtech Cardio?
Cardiovalve is a spin-off of Valtech Cardio, which was acquired by Edwards Lifesciences in 2017.

Team · 1

Amir Gross
Founder · CEO

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Materials & Substances
Target customers
Healthcare & Life SciencesHealthcareProvidersPatients
Business model
B2B

Highlights

1 Patents

Tags

doctorscatheterssurgeryvalveshospitalsmedical-devicescardiologyheart-diseasesminimally-invasive
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitecardiovalve.com
LinkedInlinkedin.com/company/33191238

Identifiers & details

Legal nameCardiovalve Ltd.
Former namesMITRALTECH
Founded2010
Employees (exact)125
Status reasonAcquired by Venus Medtech on Mar, 2022

Acquisitions & public offerings

Acquired by Venus Medtech 2021-12 $300.0M

Radar intelligence

Patents

EPO40

Web history (Wayback)

Domaincardiovalve.com

Certificate / subdomain footprint

Subdomains2

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)514381060
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2010-01-07
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2026
Active charges / liens1
Registry events3 — annual_report (2), charge (1)
Registered addressיהדות קנדה 1 אור יהודה

Recent registry events

DateEvent
2026-04-28דו~ח שנתי-הוספת דירקטור
2026-04-28דו~ח שנתי-הסרת דירקטור
2025-11-25רישום שעבוד